Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Philips (NYSE: PHG) has received FDA 510(k) clearance for its Liver Fat Quantification tools integrated into the EPIQ Elite and Affiniti ultrasound systems. This advancement aims to enhance early-stage fatty liver disease diagnosis, which affects about 25% of the global population. The tools will be showcased at the Radiological Society of North America annual meeting. Philips emphasizes that improved diagnostic capabilities will lead to better patient outcomes, allowing for timely lifestyle changes to mitigate liver disease progression.
Royal Philips (NYSE: PHG) announced on November 14, 2021, that its subsidiary, Philips Respironics, is addressing potential health risks linked to foam in certain sleep and respiratory devices. The company initiated a voluntary recall in June 2021. The FDA recently inspected a manufacturing facility, providing observations that will be addressed by Philips. Testing continues on new silicone replacement foam, with results showing acceptable outcomes. Philips is committed to the health of affected patients and will share findings with authorities following ongoing assessments.
Philips has received a USD 15.4 million grant from the Bill & Melinda Gates Foundation to enhance its obstetrics app development for the handheld ultrasound device, Lumify. This project aims to improve maternal healthcare, particularly in underserved communities, targeting around 2.5 billion people by 2030, with a focus on reducing pregnancy-related deaths. The initiative will empower midwives in low-income areas with AI technology, enabling early identification of complications in pregnancy, ultimately aiming to decrease both maternal and fetal mortality rates.
Royal Philips (NYSE: PHG) announces results from a real-world analysis of Medicare data showing significant benefits of intravascular ultrasound (IVUS) in peripheral vascular interventions. Key findings include a 32% reduction in major adverse limb events like amputations during lower extremity interventions among over 697,794 patients and a 31% reduction in repeat interventions, hospitalizations, or deaths during iliofemoral venous stenting. The study emphasizes IVUS's potential to optimize patient care and improve long-term health outcomes.
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG) announced its acquisition of Cardiologs, a France-based medical technology innovator specializing in AI-driven cardiac diagnostics. This strategic acquisition, enhancing Philips' cardiac care offerings, is anticipated to close in the coming months. Although financial details remain undisclosed, the integration of Cardiologs' ECG analysis capabilities is expected to improve diagnostic accuracy and clinician workflow. Cardiologs' technology, supported by 20 million ECG recordings, aligns with Philips' aim for better patient outcomes and healthcare efficiency.
Royal Philips (NYSE: PHG) announced the launch of innovative cardiology solutions in the North American market, aimed at enhancing procedural efficiency and patient outcomes. Key highlights include the debut of the IntraSight Mobile platform for interventional cardiology, featuring advanced imaging and physiological measurement capabilities. Additionally, Philips introduced the AngioSculpt Evo scoring balloon catheter and the Nexcimer laser system, both designed for improved treatment efficacy. Clinical data presented at the TCT 2021 conference showcased significant advancements in cardiovascular interventions and outcomes.
On October 28, 2021, Royal Philips (NYSE: PHG) announced a significant milestone for its Philips Capsule Medical Device Information Platform (MDIP), which has integrated with over 1,000 unique medical device models. This platform, which is now used in more than 3,000 healthcare facilities worldwide, streamlines clinical workflows and enhances collaboration among care teams by transforming clinical data into actionable insights. The recent integration efforts follow Philips' acquisition of Capsule Technologies earlier in 2021, showcasing the company’s commitment to advancing healthcare technology.
Summary not available.
Royal Philips (NYSE: PHG) announced new innovations in cancer care at the ASTRO annual meeting, including the Multimodality RT Simulation Workspace, which allows for enhanced image fusion and contouring. The company unveiled cutting-edge imaging platforms: MR – Ingenia RT XD and Spectral CT 7500, aimed at optimizing treatment planning. A strengthened partnership with Elekta aims to streamline oncology care, enhancing patient outcomes. With cancer cases expected to rise by 70% in two decades, these innovations address the growing complexity of cancer treatment and improve collaboration among healthcare providers.
Philips reported robust demand with double-digit order intake growth in Q3 2021.
Sales totaled EUR 4.2 billion, reflecting a 7.6% comparable decline due to supply chain challenges and a recall in Sleep & Respiratory Care. Income from continuing operations rose to EUR 442 million.
Order intake surged 47%, while adjusted EBITA was EUR 512 million (12.3% of sales). The company completed its Domestic Appliances divestment, yielding a EUR 2.5 billion gain. Despite supply chain issues, Philips expects low-single-digit sales growth for 2021 and anticipates a return to growth in 2022.